Outcomes of aggressive concurrent radiochemotherapy in highly selected septuagenarians with stage IIIB non-small cell lung carcinoma: Retrospective analysis of 89 patients

Lung Cancer

Volumn 81, Issue 2, 2013, Pages 226-230

  Topkan, Erkan ^a   Parlak, Cem ^a   Topuk, Savas ^a   Guler, Ozan Cem ^a   Selek, Ugur ^b  

^a BASKENT UNIVERSITY   (Turkey)

^b AMERICAN HOSPITAL   (Turkey)

Author keywords

Concurrent chemoradiotherapy; Elderly; Non small cell lung cancer; Stage IIIB; Survival outcome; Treatment tolerability

Indexed keywords

CISPLATIN;

AGED; ANEMIA; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; ESOPHAGITIS; FEMALE; GERIATRIC DISORDER; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROIMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION INJURY; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT CHANGE; WEIGHT REDUCTION;

CONCURRENT CHEMORADIOTHERAPY; ELDERLY; NON-SMALL CELL LUNG CANCER; STAGE IIIB; SURVIVAL OUTCOME; TREATMENT TOLERABILITY;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84879886200     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.05.002     Document Type: Article

References (22)

1. Wingo P.A., Cardinez C.J., Landis S.H., Greenlee R.T., Ries L.A., Anderson R.N., et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer 2003, 97:3133-3275.
2. Owonikoko T.K., Ragin C.C., Belani C.P., Oton A.B., Gooding W.E., Taioli E., et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007, 25:5570-5577.
3. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999, 17:2692-2699.
4. Curran W.J., Paulus R., Langer C.J., Komaki R., Lee J.S., Hauser S., et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011, 103:1452-1460.
5. Cox J.D., Le Chevalier T., Arriagada R., Choy H., Curran W.J., Fukuoka M., et al. Management of unresectable non- small cell carcinoma of the lung (NSCLC). Lung Cancer 2003, 42(Suppl. 1):S15-S16.
6. Semrau S., Klautke G., Virchow J.C., Kundt G., Fietkau R. Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy. Respir Med 2008, 102:210-218.
7. Fentiman I.S., Tirelli U., Monfardini S., Schneider M., Festen J., Cognetti F., et al. Cancer in the elderly: why so badly treated?. Lancet 1990, 335:1020-1022.
8. Jeremic B., Shibamoto Y., Milicic B., Milisavljevic S., Nikolic N., Dagovic A., et al. A phase II study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 1999, 44:343-348.
9. Paripati H.R., Karlin N.J., Schild S.E., Vora S.A., Dueck A.C., Ross H.J. Multimodality therapy improves survival in elderly patients with locally advanced non-small cell lung cancer-a retrospective analysis. J Geriat Oncol 2012, 3:104-110.
10. Atagi S., Kawahara M., Tamura T., Noda K., Watanabe K., Yokoyama A., et al. Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol 2005, 35:195-201.
11. Langer C.J., Hsu C., Curran W.J., Paulus R., Komaki R., Lee J.S., et al. Elderly patients with locally advanced non- small cell lung cancer benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (RTOG 9410). Proc Am Soc Clin Oncol 2002, 21. [abstract 1193].
12. Schild S.E., Stella P.J., Geyer S.M., Bonner J.A., McGinnis W.L., Mailliard J.A., et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 2003, 21:3201-3206.
13. Rocha Lima C.M., Herndon J.E., Kosty M., Clamon G., Green M.R. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer 2002, 94:181-187.
14. Atagi S., Kawahara M., Yokoyama A., Okamoto H., Yamamoto N., Ohe Y., et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol. 2012, 13(7):671-678.
15. Yavuz A.A., Topkan E., Onal C., Yavuz M.N. Prophylactic cranial irradiation in locally advanced non-small cell lung cancer: outcome of recursive partitioning analysis group 1 patients. J Exp Clin Cancer Res 2008, 27:80.
16. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999, 35:1773-1782.
17. Govindan R., Bogart J., Stinchcombe T., Wang X., Hodgson L., Kratzke R., et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol 2011, 29:3120-3125.
18. Hanna N., Neubauer M., Yiannoutsos C., McGarry R., Arseneau J., Ansari R., et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008, 26:5755-5760.
19. Auperin A., Le Pechoux C., Pignon J.P., Koning C., Jeremic B., Clamon G., et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 2006, 17:473-483.
20. Movsas B., Scott C., Sause W., Byhardt R., Komaki R., Cox J., et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 1999, 45:1143-1149.
21. Werner-Wasik M., Scott C., Cox J.D., Sause W.T., Byhardt R.W., Asbell S., et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000, 48:1475-1482.
22. Gielda B.T., Mehta P., Khan A., Marsh J.C., Zusag T.W., Warren W.H., et al. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. Int J Radiat Oncol Biol Phys 2011, 81:985-991.